Diyemono is hormones of gonads and medicaments used at pathology of genitals. Progestogens. Derivatives to a pregnadiene. Indications - treatments of endometriosis.

Structure

• 1 tablet contains 2 mg of the diyenogest;
• excipients: lactose, corn starch, maltodextrin, magnesium stearate, gipromelloza 15 sr, titan dioxide (E 171), macrogoal 4000, sodium.

Contraindication

Diemono® should not be applied in case of existence of any of the following states or diseases. If any of these states or diseases arises at application of Diemono®, administration of medicament should be stopped immediately:

• hypersensitivity to active agent or to any of the excipients which are a part of medicine;
• a venous thrombembolia in an active form;
• arterial or cardiovascular diseases in the anamnesis (for example, a myocardial infarction, a stroke, coronary heart disease);
• diabetes with defeat of vessels;
• a serious illness of a liver in the anamnesis, so far indicators of function of a liver not of norm;
• a tumor of a liver in the anamnesis (benign or malignant)
• known or expected malignant tumors dependent on sex hormones;
• vaginal bleeding of not clear etiology.

to Accept

on 1 tablet daily without interruption in administration of medicament approximately at the same time, washing down with a small amount of liquid. A pill can be taken irrespective of meal.

should take the Pill regularly, irrespective of vaginal bleeding. As soon as tablets from one packing ended, to begin to take a pill from the following packing, without taking a break in use of medicine.

does not have experience of treatment of Diemono® of patients with endometriosis longer than 15 months.

Administration of medicament can be begun with

in any day of a menstrual cycle.

Feature of application

As Diemono® contains only progestogen, it is considered that special cautions and security measures at use of medicines with content only of progestogen also concern Diemono®.

in case of existence before the beginning or continuation of therapy with application of Diemono®.

Heavy uterine bleedings

Uterine bleeding, for example, at women with an adenomyosis of a uterus or a leiomyoma of a uterus can amplify at application of Diemono®. If bleeding it is expressed and does not stop for a long time, it can lead to anemia (in certain cases heavy). In case of development of anemia it is necessary to consider expediency of the termination of reception of Diemono®.

Change of nature of bleeding

At most of patients at reception of the diyenogest on 2 mg happens change of nature of menstrual bleeding.

Pregnant women

Exist limited data on application of the diyenogest to pregnant women.

Research to animals Children do not point to direct or indirect undesirable influence on reproductive toxicity

Reception of Diemono® is not shown to children and teenagers before menarche.

Drivers

did not observe influence on ability to steer vehicles or to work with other mechanisms at the patients taking the medicaments containing diyenogest.

Overdose

Research of acute toxicity of the diyenogest do not testify about risk of development of acute side reactions in case of inadvertent reception of several daily therapeutic doses. Specific antidote is absent. Use of the diyenogest to day (that at 10-15 times exceeds a dose in structure of Diemono®) within more than 24 weeks were transferred by a dose on 20-30 mg very well.

Side effects

Side reactions it is described according to MedDRA. The most suitable term of MedDRA is applied to the description of a certain reaction and the connected states.

Side reactions most often develop within the first months after the beginning of application of Diemono® and disappear at treatment continuation. Changes of nature of menstrual bleedings, such as bloody discharges, irregular bleedings or amenorrhea can be observed. It was reported about the following side reactions at the patients receiving diyenogest 2 mg.

Storage conditions

special storage conditions. To store out of children's reach.